The Journal of Clinical Investigation (Apr 2022)

Remodeling the tumor microenvironment via blockade of LAIR-1 and TGF-β signaling enables PD-L1–mediated tumor eradication

  • Lucas A. Horn,
  • Paul L. Chariou,
  • Sofia R. Gameiro,
  • Haiyan Qin,
  • Masafumi Iida,
  • Kristen Fousek,
  • Thomas J. Meyer,
  • Margaret Cam,
  • Dallas Flies,
  • Solomon Langermann,
  • Jeffrey Schlom,
  • Claudia Palena

Journal volume & issue
Vol. 132, no. 8

Abstract

Read online

Collagens in the extracellular matrix (ECM) provide a physical barrier to tumor immune infiltration, while also acting as a ligand for immune inhibitory receptors. Transforming growth factor-β (TGF-β) is a key contributor to shaping the ECM by stimulating the production and remodeling of collagens. TGF-β activation signatures and collagen-rich environments have both been associated with T cell exclusion and lack of responses to immunotherapy. Here, we describe the effect of targeting collagens that signal through the inhibitory leukocyte-associated immunoglobulin-like receptor-1 (LAIR-1) in combination with blockade of TGF-β and programmed cell death ligand 1 (PD-L1). This approach remodeled the tumor collagenous matrix, enhanced tumor infiltration and activation of CD8+ T cells, and repolarized suppressive macrophage populations, resulting in high cure rates and long-term tumor-specific protection across murine models of colon and mammary carcinoma. The results highlight the advantage of direct targeting of ECM components in combination with immune checkpoint blockade therapy.

Keywords